Obesity-focused Zealand Pharma is buying into Generate:Biomedicines’s generative AI platform to create new multispecific drug candidates.

Original title: “Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs”

Partnership expands Bespak’s intranasal dry powder capabilities

Original title: “Bespak and SNBL agree global access deal for FDA‑approved nasal device”

While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.

Original title: “Alnylam bulls and bears fight it out after business-shaking guidance cut”

While industry leaders are unsure whether the U.S. or China will prevail, they are largely united in the belief that Europe is lagging behind.

Original title: “European biotech leaders split on US-China fight for deal dominance, survey finds”

Discover why flow paths, tubing and connectors may limit your bioprocess performance

Original title: “Decreasing process variability in fluid management systems”

An alliance with Rona Therapeutics adds to a particularly active stretch for Roche and makes the company the latest to bet on medicines that can lower levels of “visceral” fat.

Original title: “Roche extends China deal streak with $1B pact for RNAi obesity drug”

While innovative medicine supported Johnson & Johnson’s “in line” earnings for the third quarter of 2026, investors were disappointed to see older medicines carrying the bag.

Original title: “J&J’s innovative medicines carried Q3 as medtech disappoints, but newer medicines absent”

Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.

Original title: “Syndax ends fibrosis program for Niktimvo after mid-stage disappointment”

Bellwether Johnson & Johnson will kick off the third quarter earnings reporting period on Tuesday, with analysts searching for news on business development, launch execution and more.

Original title: “Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings”

Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.

Original title: “Parkinson’s cell therapy developer files to go public”